Search

Your search keyword '"Iribe, K."' showing total 3 results
Start Over Author "Iribe, K." Search Limiters Full Text
3 results on '"Iribe, K."'

1. Neutron capture reaction cross-section of 79Se through the 79Se(d,p) reaction in inverse kinematics

Author

Imai, N., primary, Dozono, M., additional, Michimasa, S., additional, Sumikama, T., additional, Ota, S., additional, Hayakawa, S., additional, Hwang, J.W., additional, Iribe, K., additional, Iwamoto, C., additional, Kawase, S., additional, Kawata, K., additional, Kitamura, N., additional, Masuoka, S., additional, Nakano, K., additional, Schrock, P., additional, Suzuki, D., additional, Tsunoda, R., additional, Wimmer, K., additional, Ahn, D.S., additional, Beliuskina, O., additional, Chiga, N., additional, Fukuda, N., additional, Ideguchi, E., additional, Kusaka, K., additional, Miki, H., additional, Miyatake, H., additional, Nagae, D., additional, Ohmika, S., additional, Ohtake, M., additional, Ong, H.J., additional, Otsu, H., additional, Sakurai, H., additional, Shimizu, H., additional, Shimizu, Y., additional, Sun, X., additional, Suzuki, H., additional, Takaki, M., additional, Takeda, H., additional, Takeuchi, S., additional, Teranishi, T., additional, Watanabe, Y., additional, Watanabe, Y.X., additional, Yako, K., additional, Yamada, H., additional, Yamaguchi, H., additional, Yang, L., additional, Yanagihara, R., additional, Yanagisawa, Y., additional, Yoshida, K., additional, and Shimoura, S., additional

Published
2024
Full Text
View/download PDF

2. Performance of the OEDO beamline

Author

Hwang, J W, primary, Michimasa, S, additional, Yamada, K, additional, Ota, S, additional, Dozono, M, additional, Imai, N, additional, Yoshida, K, additional, Yanagisawa, Y, additional, Kusaka, K, additional, Ohtake, M, additional, Matsushita, M, additional, Ahn, D S, additional, Beliuskina, O, additional, Chiga, N, additional, Chikaato, K, additional, Fukuda, N, additional, Hayakawa, S, additional, Ideguchi, E, additional, Iribe, K, additional, Iwamoto, C, additional, Kawase, S, additional, Kawata, K, additional, Kitamura, N, additional, Masuoka, S, additional, Miyatake, H, additional, Nagae, D, additional, Nakajima, R, additional, Nakamura, T, additional, Nakano, K, additional, Omika, S, additional, Otsu, H, additional, Sakurai, H, additional, Schrock, P, additional, Shimizu, H, additional, Shimizu, Y, additional, Sumikama, T, additional, Sun, X, additional, Suzuki, D, additional, Suzuki, H, additional, Takaki, M, additional, Takechi, M, additional, Takeda, H, additional, Takeuchi, S, additional, Teranishi, T, additional, Tsunoda, R, additional, Wang, H, additional, Watanabe, Y, additional, Watanabe, Y X, additional, Wimmer, K, additional, Yako, K, additional, Yamaguchi, H, additional, Yang, L, additional, Yoshida, H, additional, and Shimoura, S, additional

Published
2020
Full Text
View/download PDF

3. Phase III clinical trials comparing the immunogenicity and safety of the vero cell-derived Japanese encephalitis vaccine Encevac with those of mouse brain-derived vaccine by using the Beijing-1 strain.

Author

Miyazaki C, Okada K, Ozaki T, Hirose M, Iribe K, Yokote H, Ishikawa Y, Togashi T, and Ueda K

Subjects
Animals, Child, Child, Preschool, Humans, Infant, Japanese Encephalitis Vaccines administration & dosage, Japanese Encephalitis Vaccines isolation & purification, Mice, Vaccines, Inactivated administration & dosage, Vaccines, Inactivated adverse effects, Vaccines, Inactivated immunology, Vaccines, Inactivated isolation & purification, Vero Cells, Encephalitis, Japanese prevention & control, Japanese Encephalitis Vaccines adverse effects, Japanese Encephalitis Vaccines immunology
Abstract

The immunogenicity and safety of an inactivated cell culture Japanese encephalitis vaccine (CC-JEV) were compared with those of an inactivated mouse brain-derived Japanese encephalitis vaccine (MB-JEV) in phase III clinical multicenter trials conducted in children. The vaccines contain the same Japanese encephalitis virus strain, the Beijing-1 strain. Two independent clinical trials (trials 1 and 2) were conducted. Trial 1 was conducted in 468 healthy children. Each subject was injected with 17 μg per dose of either CC-JEV or MB-JEV, and the immunogenicity and safety of the vaccines were investigated. Trial 1 showed that CC-JEV was more immunogenic and reactive than MB-JEV at the same dose. Therefore, to adjust the immunogenicity of CC-JEV to that of MB-JEV, a vaccine that has had a good track record regarding its efficacy for a long time, trial 2 was conducted in 484 healthy children. To improve the stability, CC-JEV was converted from a liquid type to a freeze-dried type of vaccine. Each subject was injected subcutaneously with either 4 μg per dose of CC-JEV, 8 μg per dose of CC-JEV, or 17 μg per dose of MB-JEV twice, at an interval of 2 to 4 weeks, followed by an additional booster immunization 1 to 15 months after the primary immunization. Based on the results of trial 2, 4 μg per dose of the freeze-dried CC-JEV (under the label Encevac) was selected as a substitute for the MB-JEV. Encevac was approved and launched in 2011 and has since been in use as a 2nd-generation Japanese encephalitis vaccine in Japan. (These studies have been registered at the JapicCTI under registration no. JapicCTI-132063 and JapicCTI-080586 for trials 1 and 2, respectively).

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results